2024 was a pivotal year for mental health as the FDA approved significant new treatments, including Rejoyn, the first digital therapeutic for major depressive disorder.
The FDA's approval of Cobenfy for schizophrenia marked the introduction of a new drug targeting a different brain chemical system, a significant development after 30 years.
Despite failures in psychedelic treatments like MDMA for PTSD, the FDA's openness to further research signals potential advancements in mental health therapies.
With increasing demand for mental health services and limited trained professionals, the urgency for improving access to treatment highlights a critical need in society.
Collection
[
|
...
]